Enfortumab vedotin - rezultati pretrage

Europska Unija - hrvatski - EMA (European Medicines Agency)

padcev

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - antineoplastična sredstva - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Europska Unija - hrvatski - EMA (European Medicines Agency)

prolia

amgen europe b.v. - denosumab - bone resorption; osteoporosis, postmenopausal - lijekovi za liječenje bolesti kostiju - liječenje osteoporoze kod žena u postmenopauzi i muškaraca pri povećanom riziku od prijeloma. u žena u postmenopauzi, prolia značajno smanjuje rizik od prijeloma kralješnjaka, ne-kralješaka i kuka. liječenje gubitka koštane mase, povezane s hormonalnim ablacija kod muškaraca s rakom prostate je povećan rizik od prijeloma. u muškaraca s karcinomom prostate koji primaju ablaciju hormona, prolia značajno smanjuje rizik od prijeloma kralješaka.

Europska Unija - hrvatski - EMA (European Medicines Agency)

xgeva

amgen europe b.v. - denosumab - fractures, bone; neoplasm metastasis - lijekovi za liječenje bolesti kostiju - prevenciji skeletnih događaja (patološke frakture, tada se kosti, kompresija leđne moždine ili kirurški zahvat na kosti) kod odrasle osobe s naprednim malignih tumora sa dogovori koji uključuju kostiju (vidi odjeljak 5. tretman za odrasle i skeletally zrele gay s гигантоклеточная tumor kosti koji je operirati ili gdje kirurški резекция može dovesti do teških bolesti. .

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

prolia 60 mg/1 ml rastvor za injekciju u napunjenoj šprici

amicus pharma d.o.o. - denosumab - rastvor za injekciju u napunjenoj šprici - 60 mg/1 ml - 1 ml rastvora za injekciju u napunjenoj šprici sadrži 60 mg denosumaba

prolia 60 mg/1 ml rastvor za injekciju u napunjenoj šprici

amicus pharma d.o.o. - denosumab - rastvor za injekciju u napunjenoj šprici - 60 mg/1 ml - 1 ml rastvora za injekciju u napunjenoj šprici sadrži 60 mg denosumaba

Europska Unija - hrvatski - EMA (European Medicines Agency)

adcetris

takeda pharma a/s - Брентуксимаб ведотин - lymphoma, non-hodgkin; hodgkin disease - antineoplastična sredstva - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). Адцетриса indiciran za liječenje odraslih pacijenata s relaps ili vatrostalne cd30+ limfom Ходжкина (ЛХ):nakon terapije, orfollowing barem dva do terapije nakon terapije ili мультиагентной kemoterapije-to nije opcija liječenja . sistem анапластическая крупноклеточная lymphomaadcetris u kombinaciji s ciklofosfamid, doksorubicin i prednizon (chp) je prikazana za odrasle pacijente s prethodno liječenih liječenje sistemske анапластической veliki stanica limfoma (salcl). Адцетриса indiciran za liječenje odraslih pacijenata s relaps ili vatrostalne salcl. kožni t-stanica lymphomaadcetris indiciran za liječenje odraslih bolesnika s cd30+ stanica kožni t limfom (ctcl), nakon što je najmanje 1 do sistemske terapije.

Europska Unija - hrvatski - EMA (European Medicines Agency)

polivy

roche registration gmbh - polatuzumab ведотин - limfom, b-stanični - antineoplastična sredstva - Полевий u kombinaciji s Бендамустин i rituksimab je indiciran za liječenje odraslih bolesnika s ponavljajućom/uporan da bi se raspršili u-крупноклеточной limfoma (ДВККЛ), koji nisu kandidati za transplantaciju гемопоэтических transplantacija matičnih stanica. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

polivy 140 mg/1 bočica prašak za koncentrat za otopinu za infuziju

roche d.o.o.roche ltd. - polatuzumab ведотин - prašak za koncentrat za otopinu za infuziju - 140 mg/1 bočica - 1 bočica od 20 ml sadrži: 140 mg polatuzumab vedotina

adcetris 50 mg/1 viala prašak za koncentrat za otopinu za infuziju

takeda pharmaceuticals bh d.o.o. sarajevo - brentuksimab ведотин - prašak za koncentrat za otopinu za infuziju - 50 mg/1 viala - 1 bočica praška za koncentrat za otopinu za infuziju sadrži: 50 mg brentuksimab vedotina

Europska Unija - hrvatski - EMA (European Medicines Agency)

opdivo

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - antineoplastična sredstva - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.